# Expedited Programs for Serious Conditions | Drugs and Biologics - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/expedited-programs-for-serious-conditions-drugs-and-biologics/d49c172d-43db-4e76-a0fd-1f51de9ecff3

> FDA guidance document: Expedited Programs for Serious Conditions | Drugs and Biologics. Issue date: May 30, 2014. Get complete insights and analysis.

---

## Details

- Title: Expedited Programs for Serious Conditions | Drugs and Biologics
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2014-05-30
- Last Changed: 2023-12-14
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2013-D-0575">FDA-2013-D-0575</a>

## Related Documents

- [Dear Health Care Provider Letters: Improving Communication of Important Safety Information](https://www.globalkeysolutions.net/guidances/guidance-document/dear-health-care-provider-letters-improving-communication-of-important-safety-information/a3ea6356-848d-4286-86e9-8ac6013377e1)
- [CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports](https://www.globalkeysolutions.net/guidances/guidance-document/cmc-postapproval-manufacturing-changes-to-be-documented-in-annual-reports/67341cfe-8a48-4fc7-9817-6f9ed89768cf)
- [User Fee Waivers, Reductions, and Refunds for Drug and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/user-fee-waivers-reductions-and-refunds-for-drug-and-biological-products/ff74c3d1-95d4-4808-9bba-25a26706e7e4)